Texas Children's Hospital

Alzeca Biosciences, LLC

Carlo Medici

Ananth V Annapragada

Eric A Tanifum

Qingshan Mu

Xianwei Sun

A liposomal composition ('ADx-003') is provided, ADx-003 comprising a first phospholipid; a sterically bulky excipient that is capable of stabilizing the liposomal composition; a second phospholipid that is derivatized with a first polymer; a macrocyclic gadolinium-based imaging agent; and a third phospholipid that is derivatized with a second polymer, the second polymer being conjugated to a targeting ligand, the targeting ligand being represented by Formula I: wherein X is &#x2014;CH&#x2014;, &#x2014;CH&#x2014;CH&#x2014;, &#x2014;CHO&#x2014;, or &#x2014;O&#x2014;CO&#x2014;; Y is &#x2014;CH&#x2014;CH&#x2550;CH&#x2014; or A and B are independently selected from C and N; R, R, R, and Rare independently selected from &#x2014;H, halogen, &#x2014;OH, and &#x2014;CH; and R, R, and Rare independently selected from &#x2014;H, halogen, &#x2014;OH, &#x2014;OCH, &#x2014;NO, &#x2014;N(CH), C-Calkyl, or a substituted or unsubstituted C-Caryl group, except that when A and/or B is N the adjacent Rand/or Ris &#x2014;H, or a pharmaceutically acceptable salt thereof.

Targeted contrast agents for MRI of alpha-synuclein deposition

Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

Growing community of inventors

Reno, NV, United States of America

Carlo Medici